Regeneron News and Research

RSS
Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Eylea can ease vision problems for wet AMD patients

Eylea can ease vision problems for wet AMD patients

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Regeneron Pharmaceuticals expands ophthalmology portfolio

Regeneron Pharmaceuticals expands ophthalmology portfolio

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Regeneron fourth quarter total revenues increase to $415 million

Regeneron fourth quarter total revenues increase to $415 million

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

EC approves Regeneron’s EYLEA for treatment of wet AMD

EC approves Regeneron’s EYLEA for treatment of wet AMD

Ranibizumab injections keep those with AMD driving longer

Ranibizumab injections keep those with AMD driving longer

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

New cholesterol lowering drugs on the horizon

New cholesterol lowering drugs on the horizon